The Expression Levels of Transforming Growth Factor β1 and Tumor Necrosis Factor Receptor Associated Factor 6 in Allergic Rhinitis Patients and Their Potential Relationship with Epithelial - Mesenchymal Transition: A Pilot Prospective Observational Study.

IF 3.7 3区医学 Q2 ALLERGY

Journal of Asthma and Allergy Pub Date : 2024-11-01 eCollection Date: 2024-01-01 DOI:10.2147/JAA.S474445

Kai Wang, Qin Gao, Yelong Bai, Rong Yu, Qing Luo

{"title":"The Expression Levels of Transforming Growth Factor β1 and Tumor Necrosis Factor Receptor Associated Factor 6 in Allergic Rhinitis Patients and Their Potential Relationship with Epithelial - Mesenchymal Transition: A Pilot Prospective Observational Study.","authors":"Kai Wang, Qin Gao, Yelong Bai, Rong Yu, Qing Luo","doi":"10.2147/JAA.S474445","DOIUrl":null,"url":null,"abstract":"Objective: To study the role of transforming growth factor beta 1 (TGF-β1) and tumor necrosis factor receptor related factor 6 (TRAF6) in the progression of epithelial mesenchymal transformation (EMT) in allergic rhinitis (AR).Methods: A total of 30 patients underwent nasal endoscopic surgery at our Hospital were selected for 15 patients in each group based on their allergy status. Inferior turbinate mucosa tissue was obtained and analyzed using immunohistochemical (IHC) tests, real-time quantitative PCR (qRT-PCR) detection, and Western blotting (WB) tests to measure TGF-β1, TRAF6, E-cadherin, Vimentin, and α-Smooth Muscle Actin (α-SMA) expression levels.Results: The expression levels of TGF-β1, TRAF6, Vimentin, and α-SMA were significantly higher in the AR group compared to the control group as shown by IHC, qRT-PCR, and WB (P < 0.05). E-cadherin expression was significantly lower group than in the control group (P < 0.05). Protein expression of TGF-β1 showed significantly positive correlations with TRAF6 (r = 0.8188, P = 0.0002), α-SMA (r = 0.8076, P = 0.0003), and Vimentin (r = 0.6917, P = 0.0043). There was a significantly negative correlation between protein expression of TGF-β1 and E-cadherin (r = -0.8032, P = 0.0003). Protein expression of TRAF6 showed a significantly negative correlation with E-cadherin (r = -0.6405, P = 0.0101) but positive correlations with α-SMA (r = 0.5809, P = 0.0231) and Vimentin (r = 0.555, P = 0.0318).Conclusion: TGF-β1, TRAF6, and EMT-related markers (Vimentin, α-SMA) were highly expressed in the nasal mucosa of AR patients. TGF-β1 and TRAF6 may be involved in the epithelial-mesenchymal transition in allergic rhinitis.","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537165/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma and Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JAA.S474445","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To study the role of transforming growth factor beta 1 (TGF-β1) and tumor necrosis factor receptor related factor 6 (TRAF6) in the progression of epithelial mesenchymal transformation (EMT) in allergic rhinitis (AR).

Methods: A total of 30 patients underwent nasal endoscopic surgery at our Hospital were selected for 15 patients in each group based on their allergy status. Inferior turbinate mucosa tissue was obtained and analyzed using immunohistochemical (IHC) tests, real-time quantitative PCR (qRT-PCR) detection, and Western blotting (WB) tests to measure TGF-β1, TRAF6, E-cadherin, Vimentin, and α-Smooth Muscle Actin (α-SMA) expression levels.

Results: The expression levels of TGF-β1, TRAF6, Vimentin, and α-SMA were significantly higher in the AR group compared to the control group as shown by IHC, qRT-PCR, and WB (P < 0.05). E-cadherin expression was significantly lower group than in the control group (P < 0.05). Protein expression of TGF-β1 showed significantly positive correlations with TRAF6 (r = 0.8188, P = 0.0002), α-SMA (r = 0.8076, P = 0.0003), and Vimentin (r = 0.6917, P = 0.0043). There was a significantly negative correlation between protein expression of TGF-β1 and E-cadherin (r = -0.8032, P = 0.0003). Protein expression of TRAF6 showed a significantly negative correlation with E-cadherin (r = -0.6405, P = 0.0101) but positive correlations with α-SMA (r = 0.5809, P = 0.0231) and Vimentin (r = 0.555, P = 0.0318).

Conclusion: TGF-β1, TRAF6, and EMT-related markers (Vimentin, α-SMA) were highly expressed in the nasal mucosa of AR patients. TGF-β1 and TRAF6 may be involved in the epithelial-mesenchymal transition in allergic rhinitis.

查看原文本刊更多论文

过敏性鼻炎患者体内转化生长因子β1和肿瘤坏死因子受体相关因子6的表达水平及其与上皮-间质转化的潜在关系：一项试验性前瞻性观察研究。

目的研究转化生长因子β1（TGF-β1）和肿瘤坏死因子受体相关因子6（TRAF6）在过敏性鼻炎（AR）上皮间质转化（EMT）过程中的作用：方法：在本院接受鼻内窥镜手术的 30 例患者中，根据过敏状态选择每组 15 例患者。获取下鼻甲粘膜组织，通过免疫组化（IHC）检测、实时定量 PCR（qRT-PCR）检测和 Western 印迹（WB）检测来分析 TGF-β1、TRAF6、E-adherin、Vimentin 和 α-平滑肌肌动蛋白（α-SMA）的表达水平：IHC、qRT-PCR和WB结果显示，与对照组相比，AR组的TGF-β1、TRAF6、Vimentin和α-SMA表达水平明显升高（P < 0.05）。AR组的E-cadherin表达明显低于对照组（P＜0.05）。TGF-β1 蛋白表达与 TRAF6（r = 0.8188，P = 0.0002）、α-SMA（r = 0.8076，P = 0.0003）和 Vimentin（r = 0.6917，P = 0.0043）呈显著正相关。TGF-β1 蛋白表达与 E-cadherin 蛋白表达呈明显负相关（r = -0.8032，P = 0.0003）。TRAF6的蛋白表达与E-cadherin呈明显负相关（r = -0.6405，P = 0.0101），但与α-SMA（r = 0.5809，P = 0.0231）和Vimentin（r = 0.555，P = 0.0318）呈正相关：结论：TGF-β1、TRAF6 和 EMT 相关标记物（Vimentin、α-SMA）在 AR 患者的鼻粘膜中高表达。TGF-β1和TRAF6可能参与了过敏性鼻炎的上皮-间质转化过程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Asthma and Allergy Medicine-Immunology and Allergy

CiteScore

5.30

自引率

6.20%

发文量

185

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.